Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
Invivyd, Inc. director Ajay Royan received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 annual stockholders meeting, subject to Royan’s continuous service. Following this grant, he holds 50,000 options directly.
Invivyd, Inc. director Kevin F. McLaughlin received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. They vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, conditioned on his continuous service through that vesting date.
Invivyd, Inc. director Terrance McGuire received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. All 50,000 options were reported as directly owned following this grant.
According to the award terms, the option vests in full on the earlier of May 19, 2027 or the date of Invivyd’s 2027 annual meeting of stockholders, as long as McGuire continues to serve the company through that vesting date. This is a compensation-related grant, not an open‑market purchase or sale.
Invivyd, Inc. reported that director Marc Elia received a grant of stock options covering 50,000 shares of common stock at an exercise price of $1.04 per share. The options vest in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to his continuous service, and expire on May 18, 2036. Following this award, Elia holds 50,000 stock options, which he is deemed to hold for the benefit of M28 Capital Management LP and funds managed by that firm.
Invivyd, Inc. reported that director Paul Bolno received a grant of stock options covering 32,876 shares of common stock. The options have an exercise price of $1.04 per share and expire on May 18, 2036. The grant vests in full on the earlier of May 19, 2027 or the date of Invivyd's 2027 Annual Meeting of Stockholders, provided he continues in service through that vesting date. After this grant, Bolno holds options for 32,876 underlying shares directly.
Invivyd, Inc. director Tamsin Berry received a compensation-related stock option grant covering 50,000 shares of common stock. The option has an exercise price of $1.0400 per share and expires on May 18, 2036. It vests in full on the earlier of May 19, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to her continuous service through the vesting date. Following this grant, she holds stock options for 50,000 shares directly.
Invivyd, Inc. reported voting results from its Annual Meeting of Stockholders held on May 19, 2026. Stockholders elected six directors — Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan — each for a one-year term ending at the 2027 annual meeting.
Each director nominee received over 173 million votes in favor, with additional broker non-votes recorded. Stockholders also ratified PricewaterhouseCoopers LLP as Invivyd’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 222,576,623 votes for, 80,390 against and 44,315 abstentions.
RA Capital Management and affiliated filers amended their Schedule 13G to report beneficial ownership tied to pre-funded warrants for Invivyd, Inc. The amendment states the Fund holds Pre-Funded Warrants exercisable for 21,342,442 shares of Common Stock and reports 7.0% of the class as of March 31, 2026.
The percentage is calculated using 282,803,863 shares outstanding as of March 20, 2026 plus the 21,342,442 shares issuable upon exercise of the Pre-Funded Warrants. The filing discloses that voting and dispositive power over the Fund's holdings has been delegated to RA Capital and contains standard disclaimers of beneficial ownership by the advisers and principals.
Invivyd, Inc. reporting persons Point72 Asset Management, Point72 Capital Advisors, Inc. and Steven A. Cohen filed an Amendment No. 3 to a Schedule 13G/A stating shared beneficial ownership of 43,931 shares of common stock. The ownership figure is reported as of the close of business on March 31, 2026.
The cover-page rows show shared voting power and shared dispositive power of 43,931 for each reporting person. The amendment lists the reporting persons' principal business address and is signed by an authorized person on May 15, 2026.
Invivyd, Inc. reported higher product revenue but significantly larger losses for the quarter ended March 31, 2026. Revenue rose to $13.7 million from $11.3 million, driven by sales of its COVID-19 antibody PEMGARDA. Operating costs climbed sharply, with research and development at $30.7 million and selling, general and administrative at $25.1 million, leading to a net loss of $41.4 million, up from $16.3 million a year earlier.
Cash and cash equivalents fell to $184.2 million from $226.7 million at year-end, with operating cash outflows of $41.7 million in the quarter and an accumulated deficit of $995.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond one year without additional financing. Invivyd continues advancing its pipeline, including Phase 3 trials for COVID-19 antibody VYD2311 and preclinical RSV and measles programs, while also maintaining access to an undrawn senior loan facility and an at-the-market equity program.